Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Satellos Bioscience ( (TSE:MSCL) ).
Satellos Bioscience has presented promising initial data from its Phase 1 trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The Phase 1a results demonstrated that SAT-3247 was safe and well-tolerated in 72 healthy volunteers, showing a favorable pharmacokinetic profile, which supports its potential as a novel oral therapy for Duchenne Muscular Dystrophy. The ongoing Phase 1b trial is enrolling adults with DMD to further assess safety and pharmacokinetics, with full data expected in Q2 2025. This development could significantly impact the treatment landscape for DMD and other muscle degeneration conditions, offering hope for improved therapeutic options.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage drug development company focused on creating innovative small molecule therapies for degenerative muscle diseases. The company is advancing SAT-3247, a first-of-its-kind oral drug designed to restore skeletal muscle regeneration by correcting muscle stem cell polarity, targeting conditions like Duchenne Muscular Dystrophy (DMD) regardless of exon mutation status.
YTD Price Performance: -4.92%
Average Trading Volume: 141,438
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $90.06M
For detailed information about MSCL stock, go to TipRanks’ Stock Analysis page.